Abstract
The purpose of this study was to predict chemotherapy response by technetium-99m methoxy-isobutylisonitrile (Tc-99m MIBI) lung single-photon-emission computed tomography (SPECT) and compare P-glycoprotein (Pgp) expression in patients with untreated small cell lung cancer (SCLC). Before chemotherapy, 40 patients with untreated SCLC underwent Tc-99m MIBI lung SPECT. Immunohistochemical analyses were performed using multiple nonconsecutive sections of the biopsy specimens to detect Pgp expression. Chemotherapy response was evaluated in the third month after completion of treatment by clinical and radiological methods. Based on quantitative analyses, the tumor uptake ratios (TUR) of the 20 patients with good response (1.89±0.28) were significantly higher than that of the 20 patients with poor response (1.21±0.28) (p value<0.05). Based on visual interpretation, all of the 20 patients (100%) with good response had positive Tc-99m TF lung SPECT findings and negative Pgp expression. Five of the other 20 patients (25%) with poor response had positive Tc-99m MIBI lung SPECT findings, and 12 of the other 20 patients (60%) with poor response had negative Pgp expression (p value<0.05). Negative Tc-99m MIBI lung SPECT findings could predict poor response. Therefore, we concluded that Tc-99m MIBI lung SPECT can accurately predict the chemotherapy response, and Tc-99m MIBI lung SPECT findings can be partially compatible with Pgp expression in patients with untreated SCLC.
Similar content being viewed by others
References
Lassen U, Hansen HH: Small cell carcinoma of the lung. In Cancer treatment, edited by CM Haskell, JS Berek, Philadelphia, W B Saunders, 1995, pp. 414–420.
Smit EF, Postmus PE: Chemotherapy of small cell lung cancer. In Carney DN (ed). Lung cancer. The Bath Press, Avon, London, 1995, pp. 156–172.
Berlin J, Schiller JH: Chemotherapy of small-cell carcinoma of the lung. In Johnson BE, Johnson DH (eds). Lung cancer. Wiley-Liss, New York, 1995, pp. 247–261.
Oka M, et al. The clinical role of MDR1 gene expression in human lung cancer. Anticancer Res 1997;17:721–724.
Twentyman PR. Mechanism of drug resistance in lung cancer cells. In Carney DN (ed). Lung cancer. The Bath Press, Avon, London. 1995.
Beck W, Dalton WS: Mechanisms of drug resistance. In DeVita VT Jr, et al. (eds.) Cancer: principles and practice of oncology. JB Lippincott, Philadelphia, 1997.
Piwnica-Worms D, et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977–984.
Hendrikse NH, et al. Visualization of multidrug resistance in vivo. Eur J Nucl Med 1999;26:283–293.
Vergote J, et al. Comparison of the kinetics of active efflux of 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes. Eur J Biochem 1998;252:140–146.
Hendrikse NH, et al. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer 1998;77:353–358.
Yamamoto Y, et al. Comparative study of technetium-99m-sestamibi and thallium-201 SPECT in predicting chemotherapeutic response in small cell lung cancer. J Nucl Med 1998;39:1626–1629.
Kao CH, et al. Technetium-99m methoxyisobutylisonitrile chest imaging of sinall cell lung carcinoma: relation to patient prognosis and chemotherapy response—a preliminary report. Cancer 1998;83:64–68.
Kao CH, et al. Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single photon emission computed tomography. Clin Cancer Res 2000;6:820–824.
Oken MM, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.
Aktolun C, et al. Assessment of tumour necrosis and detection of mediastinal lymph node metastasis in bronchial carcinoma with technetium-99m MIBI imaging: comparison with CT scan. Eur J Nucl Med 1994;21:973–979.
Kao CH, et al. Differentiation of single solid lesions in the lungs by means of single-photon emission tomography with technetium-99m methoxyisobutylisonitrile. Eur J Nucl Med 1993;20:249–254.
Kostakoglu L, et al. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med 1998;39:228–234.
Kreisholt J, et al. Immunohistochemical defection of DNA topoisomerases II α, p-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer. Br J Cancer 1998;77:1469–1473.
Chuman Y, et al. Expression of the multidrug-resistance-associated protein (MRP) gene in human colorectal, gastric and non-small-cell lung carcinomas. Int J Cancer 1996;66:274–279.
Karnofsky DA, et al. The use of nitrogen mustards in the palliative treatment of cancer. Cancer 1948;1:634–656.
Neal AJ, Hoskin PJ: Lung cancer and mesothelioma. In Neal AJ, Hoskin PJ (eds). Clinical oncology: basic principles and practice. Arnold, London, 1997, pp. 42–55.
Canitrot Y, et al. Multidrug resistance genes (MRP) and MDRI expression in small cell lung cancer xenografts: relationship with response to chemotherapy. Cancer Lett 1998;130:133–141.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Changlai, SP., Tsai, CS., Ding, HJ. et al. Using technetium-99m methoxyisobutylisonitrile lung single-photon-emission computed tomography to predict response to chemotherapy and compare with p-glycoprotein expression in patients with untreted small cell lung cancer. Med Oncol 20, 247–253 (2003). https://doi.org/10.1385/MO:20:3:247
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/MO:20:3:247